Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Document Type
Year range
1.
ASAIO Journal ; 67(SUPPL 3):20, 2021.
Article in English | EMBASE | ID: covidwho-1481480

ABSTRACT

Introduction: Patients with severe COVID-19 may develop sepsis-like syndrome that can progress to multiple organ failure and ultimately death. Underlying mechanism have been explored and suggest a profound dysregulation of the immune system associated with hyperinflammation, hemodynamic instability and respiratory failure. Approaches modulating the dysregulated immune response, such as CytoSorb hemoadsorption, have been used. However, data of ECMO-dependent patients in comparison to a control cohort remain scarce. Patients and methods: Included were 26 critically ill COVID-19 patients requiring high-flow veno-venous extracorporeal membrane oxygenation (VV ECMO) therapy due to severe ARDS, of whom 16 were additionally treated with an extracorporeal hemoadsorption device, and compared to a control group of 10 patients. Assessed were levels of inflammatory markers, vasopressor requirements, as well as clinically relevant outcome variables. Results: Treatment with the applied multimodal therapy approach resulted in a stabilization in hemodynamics, a control of the hyperinflammatory response as evidenced by a significant reduction in inflammatory mediators, as well as a marked improvement in lung function. No device related adverse events were observed while treatment appeared safe and feasible. Conclusions: Treatment of critically ill COVID-19 patients with respiratory failure requiring VV ECMO support and hemoadsorption therapy led to a rapid and sustained hemodynamic stabilization, a control of inflammatory response and an improvement in oxygenation. Given these signals pointing towards a patient-oriented benefit of extracorporeal hemoadsorption therapy in those patients, future controlled, randomized studies should focus on the investigation of the appropriate timing and dosing of this promising treatment modality.

2.
Unfallchirurg ; 124(5): 358-361, 2021 May.
Article in German | MEDLINE | ID: covidwho-1217422

ABSTRACT

The coronavirus disease 2019 (COVID-19) has spread rapidly worldwide and leads to high morbidity and mortality. Clinical experience regarding the surgical management in COVID-19 patients is limited. We report the interdisciplinary approach in a COVID-19 patient with severe thoracic trauma and pulmonary symptoms, who was admitted to the emergency unit after blunt chest trauma with dislocated serial rib fractures and concomitant hemothorax.


Subject(s)
COVID-19 , Rib Fractures , Thoracic Injuries , Wounds, Nonpenetrating , Aged , Humans , Rib Fractures/complications , Rib Fractures/diagnostic imaging , Rib Fractures/surgery , SARS-CoV-2 , Thoracic Injuries/diagnostic imaging , Thoracic Injuries/surgery
SELECTION OF CITATIONS
SEARCH DETAIL